Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

by Sauerhering, Lucie , Cai, Zheng , Schiele, Felix , Schmidt, Jörg , Vanshylla, Kanika , Liberta, Falk , Becker, Stephan , Zehner, Matthias , Becker, Nico , Kämper, Lennart , Rohde, Cornelius , Widera, Marek , Yang, Guangwei , Klein, Florian , Krähling, Verena , Han, Fei , Gruell, Henning , Halwe, Sandro , Koch, Manuel , Kupke, Alexandra , Gellhorn Serra, Michelle , Kreer, Christoph , Klüver, Michael , Ciesek, Sandra , Werner, Anke , Eickmann, Markus , Young, David , Marlow, Michael S.

in animal experiments / Antibodies / Antiviral agents / Antiviral drugs / Bioavailability / Clinical trials / Coronaviruses / COVID-19 / Disease transmission / humans / Intranasal administration / intravenous injection / Laboratories / lungs / mice / Microscopy / Monoclonal antibodies / monoclonal antibody / neutralizing antibody / pandemic / Pandemics / Pharmacokinetics / Proteins / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus / Severe acute respiratory syndrome coronavirus 2 / Software / Spike protein / virus

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

2021

Confirm

Do you wish to request the book?

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Sauerhering, Lucie,

Cai, Zheng,

Schiele, Felix,

Schmidt, Jörg,

Vanshylla, Kanika,

Liberta, Falk,

Becker, Stephan,

Zehner, Matthias,

Becker, Nico,

Kämper, Lennart,

Rohde, Cornelius,

Widera, Marek,

Yang, Guangwei,

Klein, Florian,

Krähling, Verena,

Han, Fei,

Gruell, Henning,

Halwe, Sandro,

Koch, Manuel,

Kupke, Alexandra,

Gellhorn Serra, Michelle,

Kreer, Christoph,

Klüver, Michael,

Ciesek, Sandra,

Werner, Anke,

Eickmann, Markus,

Young, David,

Marlow, Michael S.

2021

Overview

Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.

Share this book

Add to My Shelf

Publisher

MDPI AG,MDPI

Subject